Mannatech Incorporated (MTEX) and DERMAdoctor LLC. (NASDAQ:DDOC) Contrasting side by side

Mannatech Incorporated (NASDAQ:MTEX) and DERMAdoctor LLC. (NASDAQ:DDOC) compete with each other in the Personal Products sector. We will analyze and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mannatech Incorporated 175.91M 0.26 6.03M -2.41 0.00
DERMAdoctor LLC. N/A 0.00 N/A -0.12 0.00

Table 1 demonstrates Mannatech Incorporated and DERMAdoctor LLC.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 demonstrates the return on assets, return on equity and net margins of Mannatech Incorporated and DERMAdoctor LLC.

Net Margins Return on Equity Return on Assets
Mannatech Incorporated -3.43% -17.3% -8.2%
DERMAdoctor LLC. 0.00% 0% 0%


Mannatech Incorporated dividend pay is $1.25 per share with 6.53% dividend yield annually. No dividend is paid out for DERMAdoctor LLC.

Insider & Institutional Ownership

Institutional investors owned 16.6% of Mannatech Incorporated shares and 0% of DERMAdoctor LLC. shares. Mannatech Incorporated’s share owned by insiders are 2.8%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Mannatech Incorporated 3.36% 18.06% -2.39% -5.21% 37.93% 33.33%
DERMAdoctor LLC. 0% 0% 0% 0% 0% 0%

Mannatech, Incorporated operates as a wellness solution provider. It develops and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. The company markets its products through network marketing channel in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. Mannatech, Incorporated was founded in 1993 and is headquartered in Coppell, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.